These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 933229)

  • 1. Use of amphotericin B in mucocutaneous leishmaniasis.
    Crofts MA
    J Trop Med Hyg; 1976 May; 79(5):111-3. PubMed ID: 933229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [South american mucocutaneous Leishmaniasis in the region of the Rio Pachitea (author's transl)].
    Heimgartner E; Heimgartner V
    Dermatologica; 1974; 149(4):248-52. PubMed ID: 4376499
    [No Abstract]   [Full Text] [Related]  

  • 3. [American leishmaniasis of the skin and mucous membranes and its treatment with amphotericin B (author's transl)].
    Mayer PJ
    MMW Munch Med Wochenschr; 1974 Sep; 116(36):1539-46. PubMed ID: 4215958
    [No Abstract]   [Full Text] [Related]  

  • 4. [South American leishmaniasis in medical practice. Therapeutic problems].
    Heimgartner E; Krebs A
    Schweiz Rundsch Med Prax; 1985 Jul; 74(29):779-83. PubMed ID: 3898301
    [No Abstract]   [Full Text] [Related]  

  • 5. Liposomal formulation of amphotericin B for the treatment of mucosal leishmaniasis in HIV-negative patients.
    Rocio C; Amato VS; Camargo RA; Tuon FF; Nicodemo AC
    Trans R Soc Trop Med Hyg; 2014 Mar; 108(3):176-8. PubMed ID: 24535153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Amphotericin B in the treatment of otorhinolaryngologic forms of paracoccidioidosis and leishmaniasis resistant to sulf as the antimonials].
    Albernaz PL; Lanzellotti WP; Ganança MM
    Hospital (Rio J); 1968 Sep; 74(3):913-20. PubMed ID: 5303774
    [No Abstract]   [Full Text] [Related]  

  • 7. [Mucocutaneous lesions produced by Leishmania Braziliensis].
    Lasala Carreras A
    Acta Odontol Venez; 1974 Apr; 12(1):3-21. PubMed ID: 4535200
    [No Abstract]   [Full Text] [Related]  

  • 8. [Amphotericin B in the treatment of the otorhinolaryngological forms of paracoccidioidomycosis and leishmaniasis resistent to sulfas and antimonial agents].
    Albernaz PL; Lanzellotti WP; Ganança MM
    Hospital (Rio J); 1968 Sep; 74(3):913-20. PubMed ID: 5310129
    [No Abstract]   [Full Text] [Related]  

  • 9. [Experience with endemic dermatological diseases in the Peruvian wilderness: mucocutaneous leishmaniasis and Brazilian foliaceous pemphigus].
    Heimgartner E; De Heimagartner V
    Med Cutan Ibero Lat Am; 1976; 4(1):1-6. PubMed ID: 135891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis.
    Sundar S; Mehta H; Chhabra A; Singh V; Chauhan V; Desjeux P; Rai M
    Clin Infect Dis; 2006 Mar; 42(5):608-13. PubMed ID: 16447104
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amphotericin B therapy in kala-azar.
    Giri OP
    J Indian Med Assoc; 1993 Apr; 91(4):91-3. PubMed ID: 8409490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of mucocutaneous (American) leishmaniasis with amphotericin B: report of 70 cases.
    Sampaio SA; Castro RM; Dillon NL; Martins JE
    Int J Dermatol; 1971; 10(3):179-81. PubMed ID: 5116171
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries.
    Berman JD; Badaro R; Thakur CP; Wasunna KM; Behbehani K; Davidson R; Kuzoe F; Pang L; Weerasuriya K; Bryceson AD
    Bull World Health Organ; 1998; 76(1):25-32. PubMed ID: 9615494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis?
    Amato VS; Tuon FF; Camargo RA; Souza RM; Santos CR; Nicodemo AC
    Am J Trop Med Hyg; 2011 Nov; 85(5):818-9. PubMed ID: 22049033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [American cutaneous and mucous leishmaniasis (mucocutaneous leishmaniasis)].
    Lieske H
    Hautarzt; 1979 Nov; 30(11):604-6. PubMed ID: 521290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study.
    Cunha MA; Leão AC; de Cassia Soler R; Lindoso JA
    Am J Trop Med Hyg; 2015 Dec; 93(6):1214-8. PubMed ID: 26483120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imported mucocutaneous leishmaniasis in New York City. Report of a patient treated with amphotericin B.
    Singer C; Armstrong D; Jones TC; Spiro RH
    Am J Med; 1975 Sep; 59(3):444-7. PubMed ID: 1163553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of mucocutaneous leishmaniasis with pentamidine isothionate].
    Amato V; Amato J; Nicodemo A; Uip D; Amato-Neto V; Duarte M
    Ann Dermatol Venereol; 1998 Aug; 125(8):492-5. PubMed ID: 9747313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions.
    Sundar S; Chakravarty J; Rai VK; Agrawal N; Singh SP; Chauhan V; Murray HW
    Clin Infect Dis; 2007 Sep; 45(5):556-61. PubMed ID: 17682988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Difficulty of treatment of South American leishmaniasis seen again at a one year interval].
    Pothier MA; Coudert J; Nobrega G; Lima Ndos S
    Bull Soc Pathol Exot Filiales; 1970; 63(4):473-6. PubMed ID: 5537232
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.